Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8WU0Q)

• Drug Name: Retatrutide Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DM8WU0Q

Molecule-Related Drug Atlas

Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Semaglutide	DMAGFOD	Type-2 diabetes	5A11	Approved	[3]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[4]
Exenatide	DMYHBKN	Inflammation	1A00-CA43.1	Approved	[5]
Dulaglutide	DMYXBV3	Type-2 diabetes	5A11	Approved	[6]
Lixisenatide	DM0QJDC	Type-2 diabetes	5A11	Approved	[7]
Pramlintide	DM0EZ9Q	Type-1/2 diabetes	5A10-5A11	Approved	[4]
Albiglutide	DM1JEGF	Type-2 diabetes	5A11	Approved	[7]
Tirzepatide	DMQNMAT	Type 2 diabetes	5A11	Approved	[8]
Efpeglenatide	DMKA2PI	Type-2 diabetes	5A11	Phase 3	[9]
GLP-1	DMR6YH3	Diabetic complication	5A2Y	Phase 3	[3]

Drug(s) Targeting Gastric inhibitory polypeptide receptor (GIPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY3437943	DMN37M6	Obesity	5B81	Phase 2	[10]
AMG 133	DMSRCIS	Obesity	5B81	Phase 2	[11]
SAR438335	DM7QO05	Type-2 diabetes	5A11	Phase 1	[9]
CT 868	DMI7XMU	Type 2 diabetes	5A11	Phase 1	[12]
CT-388	DMWHBE5	Obesity	5B81	Phase 1	[13]
LY3532226	DM9IZG3	Type 2 diabetes	5A11	Phase 1	[14]
LY3537021	DMJUXW7	Type 2 diabetes	5A11	Phase 1	[15]
RG7685	DMPQC18	Type-2 diabetes	5A11	Discontinued in Phase 2	[16]
RG7697	DMI1XQ9	Type-2 diabetes	5A11	Discontinued in Phase 2	[17]

Drug(s) Targeting Glucagon receptor (GCGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucagon recombinant	DMFLUTR	Hypoglycemia	5A41	Approved	[18]
Dasiglucagon	DM74SVE	Hypoglycemia	5A41	Approved	[19]
MK-8521	DMVNAYE	Type-2 diabetes	5A11	Phase 2	[9]
LY2944876	DML6XWR	Diabetic complication	5A2Y	Phase 2	[20]
TT-401	DMRQ0SA	Type-2 diabetes	5A11	Phase 2	[9]
LGD-6972	DMPL9KG	Type-2 diabetes	5A11	Phase 2	[21]
PF-06291874	DMN94QM	Type-2 diabetes	5A11	Phase 2	[22]
LY-2409021	DMZOIP4	Type-2 diabetes	5A11	Phase 2	[23]
REMD 477	DM13OVF	Type-1 diabetes	5A10	Phase 2	[24]
Efinopegdutide	DMAN2V2	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric inhibitory polypeptide receptor (GIPR)	TTYMKBE	GIPR_HUMAN	Agonist	[2]
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Agonist	[2]
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT05882045) A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease. U.S.National Institutes of Health.
• [2] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
• [4] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [5] Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
• [8] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
• [11] An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939.
• [12] Clinical pipeline report, company report or official report of Carmot Therapeutics.
• [13] Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [15] ClinicalTrials.gov (NCT04586907) A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
• [16] Company report (Roche pipeline: October 16, 2012)
• [17] Company report (Roche pipeline: 16 October 2014)
• [18] Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [20] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [21] Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
• [22] Clinical pipeline report, company report or official report of pfizer.
• [23] Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
• [24] Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.